Wednesday, Apr 24 2024 | Time 20:59 Hrs(IST)
image
Business EconomyPosted at: Apr 8 2020 2:47PM


Roche India announces launch of Atezolizumab for TNBC treatment

Hyderabad, Apr 8 (UNI) Roche India on Wednesday announced the launch of Atezolizumab for metastatic Triple-Negative Breast Cancer (TNBC) treatment in India.

Atezolizumab (cancer immunotherapy drug) in combination with nab-Paclitaxel (Chemotherapy) can now be used as a first-line treatment for TNBC patients.

The approval from the Drug Controller General of India (DCGI) is based on the data from phase III IMpassion130 study according to which Atezolizumab is proven to significantly reduce the risk of disease worsening or death (PFS) in the intention-to-treat and PD-L1 positive population with metastatic or unresectable locally advanced TNBC.
Roche, which has been developing medicines with the goal to redefine treatment in oncology, said in a release that aAdditionally, it has shown an encouraging Overall Survival (OS) in the PD-L1 positive population at this interim analysis.

“Atezolizumab is the first immunotherapy drug to be approved globally and in India for TNBC, an aggressive disease with very limited treatment options,” said Mr. V. Simpson Emmanuel, General Manager, Roche Products (India) Private Limited.

“Roche has been at the forefront of improving the lives of patients diagnosed with breast cancer.
This launch further strengthens our commitment to provide better outcomes for patients with unresectable locally advanced and metastatic triple-negative breast cancer in India,” Mr Emmanuel added.

Breast cancer is the most common cancer amongst women across the world affecting 2.1 million women each year.

According to Globocan 2018, over 160,000 new cases of breast cancer were in India.

TNBC is a rare type of breast cancer that experiences rapid progression and it is defined by the lack of expression and/or amplification of the targetable receptors for oestrogen, progesterone and HER2 amplification.

Triple Negative Breast Cancer represents 31 per cent of all breast cancers and is more common in women under the age of 50, compared with other forms of breast cancer, the release added.
UNI KNR CS 1445
Please log in to get detailed story.
Tags: #Roche India announces launch of Atezolizumab for TNBC treatment
More News

Dish TV revolutionises entertainment with ‘Dish TV Smart+’ services

24 Apr 2024 | 7:31 PM

Kolkata, Apr 24 (UNI) Dish TV has taken a path-breaking initiative to redefine the entertainment experience in India.

see more..

TRAI recommends sharing of active, passive infra by telecom providers

24 Apr 2024 | 7:03 PM

New Delhi, April 24 (UNI) With a view to improve quality of services and reducing cost, the telecom regulator TRAI on Wednesday recommended sharing of active and passive infrastructure among telecom service providers, a move that would help setting up network quickly across the nation.

see more..

REC to provide loan of Rs 1869 cr to Chenab Valley Power Project in J&K

24 Apr 2024 | 6:38 PM

New Delhi, April 24 (UNI) State-owned non-banking finance company REC Limited has signed an agreement with Chenab Valley Power Project Private Limited (CVPPPL), under which it will provide financial assistance of Rs 1,869.265 crore as a term loan.

see more..

Nissan establishes new Sales and Service network in Durgapur

24 Apr 2024 | 6:36 PM

Kolkata, Apr 24 (UNI) Nissan Motor India Pvt. Ltd. (NMIPL) on Wednesday unveiled a new state-of-the-art dealership and a service workshop at industrial Durgapur town in West Burdwan.

see more..

Car owners demand better roads in 2024 election survey

24 Apr 2024 | 6:35 PM

New Delhi, April 24 (UNI) In a recent Park+ survey, 98% of Indian car owners are calling for improved road infrastructure from political contenders in the 2024 Lok Sabha elections.

see more..
image